17-18135725-G-T

Variant summary

Our verdict is Uncertain significance. Variant got -1 ACMG points: 0P and 1B. BS1_Supporting

This summary comes from the ClinGen Evidence Repository: The p.Glu1499Asp variant in MYO15A has been identified in the heterozygous state in at least 4 individuals with hearing loss, 1 individual with intrauterine demise, and in 1 individual with hearing loss with a variant of uncertain significance suspected in trans (Partners LMM internal data SCV000711130.2, PMIDs: 27068579, 32304219). The filtering allele frequency (the lower threshold of the 95% CI of 59/35358) of the p.Glu1499Asp variant in the MYO15A gene is 0.13% for Latino/Admixed chromosomes by gnomAD v2.1, which is a higher frequency than would be expected for an autosomal recessive pathogenic variant based on the thresholds defined by the ClinGen Hearing Loss Expert Panel (BS1_Supporting). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel : BS1_Supporting. LINK:https://erepo.genome.network/evrepo/ui/classification/CA8423917/MONDO:0019497/005

Frequency

Genomes: 𝑓 0.00048 ( 0 hom., cov: 33)
Exomes 𝑓: 0.0011 ( 3 hom. )

Consequence

MYO15A
NM_016239.4 missense

Scores

1
9
9

Clinical Significance

Uncertain significance reviewed by expert panel U:6B:2

Conservation

PhyloP100: 2.82
Variant links:
Genes affected
MYO15A (HGNC:7594): (myosin XVA) This gene encodes an unconventional myosin. This protein differs from other myosins in that it has a long N-terminal extension preceding the conserved motor domain. Studies in mice suggest that this protein is necessary for actin organization in the hair cells of the cochlea. Mutations in this gene have been associated with profound, congenital, neurosensory, nonsyndromal deafness. This gene is located within the Smith-Magenis syndrome region on chromosome 17. Read-through transcripts containing an upstream gene and this gene have been identified, but they are not thought to encode a fusion protein. Several alternatively spliced transcript variants have been described, but their full length sequences have not been determined. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Uncertain_significance. Variant got -1 ACMG points.

BS1
For more information check the summary or visit ClinGen Evidence Repository.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
MYO15ANM_016239.4 linkc.4497G>T p.Glu1499Asp missense_variant Exon 13 of 66 ENST00000647165.2 NP_057323.3 Q9UKN7-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
MYO15AENST00000647165.2 linkc.4497G>T p.Glu1499Asp missense_variant Exon 13 of 66 NM_016239.4 ENSP00000495481.1 Q9UKN7-1

Frequencies

GnomAD3 genomes
AF:
0.000480
AC:
73
AN:
152202
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.000265
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.000786
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000705
Gnomad OTH
AF:
0.000955
GnomAD3 exomes
AF:
0.000798
AC:
199
AN:
249272
Hom.:
2
AF XY:
0.000717
AC XY:
97
AN XY:
135304
show subpopulations
Gnomad AFR exome
AF:
0.000259
Gnomad AMR exome
AF:
0.00168
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.00113
Gnomad OTH exome
AF:
0.00149
GnomAD4 exome
AF:
0.00108
AC:
1577
AN:
1461830
Hom.:
3
Cov.:
31
AF XY:
0.00105
AC XY:
762
AN XY:
727212
show subpopulations
Gnomad4 AFR exome
AF:
0.000179
Gnomad4 AMR exome
AF:
0.00186
Gnomad4 ASJ exome
AF:
0.0000383
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00
Gnomad4 FIN exome
AF:
0.00
Gnomad4 NFE exome
AF:
0.00129
Gnomad4 OTH exome
AF:
0.000894
GnomAD4 genome
AF:
0.000479
AC:
73
AN:
152320
Hom.:
0
Cov.:
33
AF XY:
0.000403
AC XY:
30
AN XY:
74480
show subpopulations
Gnomad4 AFR
AF:
0.000265
Gnomad4 AMR
AF:
0.000785
Gnomad4 ASJ
AF:
0.00
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00
Gnomad4 FIN
AF:
0.00
Gnomad4 NFE
AF:
0.000706
Gnomad4 OTH
AF:
0.000945
Alfa
AF:
0.000962
Hom.:
0
Bravo
AF:
0.000623
TwinsUK
AF:
0.00216
AC:
8
ALSPAC
AF:
0.00130
AC:
5
ESP6500AA
AF:
0.000240
AC:
1
ESP6500EA
AF:
0.00142
AC:
12
ExAC
AF:
0.000810
AC:
98
EpiCase
AF:
0.00104
EpiControl
AF:
0.00107

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:6Benign:2
Revision: reviewed by expert panel
LINK: link

Submissions by phenotype

not provided Uncertain:2Benign:1
Dec 04, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Sep 16, 2021
GeneDx
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Reported in a patient with hearing loss in published literature; however, clinical information was limited (Sommen M et al., 2016); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 27068579, 32304219) -

-
Breakthrough Genomics, Breakthrough Genomics
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: not provided

- -

Autosomal recessive nonsyndromic hearing loss 3 Uncertain:2
Apr 27, 2017
Illumina Laboratory Services, Illumina
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. -

Sep 03, 2021
Fulgent Genetics, Fulgent Genetics
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not specified Uncertain:1
Mar 19, 2019
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The p.Glu1499Asp variant in MYO15A has been identified in at least 5 individuals with hearing loss, only 1 of whom carried a second variant (classified as a VUS) in MYO15A (Sommen 2016, LMM data). This variant has also been identified in 0.17% (59/35358) of Latino and 0.11% (141/128518) of European chromosomes, including 2 homozygotes, by gnomAD (http://gnomad.broadinstitute.org). Computational prediction tools and conservation analysis suggest that the variant may impact the protein, though this information is not predictive enough to determine pathogenicity. In summary, the clinical significance of the p.Glu1499Asp variant is uncertain. ACMG/AMP Criteria applied: BS1_Supporting, PP3. -

Nonsyndromic genetic hearing loss Uncertain:1
Jun 15, 2021
ClinGen Hearing Loss Variant Curation Expert Panel
Significance: Uncertain significance
Review Status: reviewed by expert panel
Collection Method: curation

The p.Glu1499Asp variant in MYO15A has been identified in the heterozygous state in at least 4 individuals with hearing loss, 1 individual with intrauterine demise, and in 1 individual with hearing loss with a variant of uncertain significance suspected in trans (Partners LMM internal data SCV000711130.2, PMIDs: 27068579, 32304219). The filtering allele frequency (the lower threshold of the 95% CI of 59/35358) of the p.Glu1499Asp variant in the MYO15A gene is 0.13% for Latino/Admixed chromosomes by gnomAD v2.1, which is a higher frequency than would be expected for an autosomal recessive pathogenic variant based on the thresholds defined by the ClinGen Hearing Loss Expert Panel (BS1_Supporting). In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Hearing Loss Expert Panel : BS1_Supporting. -

MYO15A-related disorder Benign:1
Jun 29, 2022
PreventionGenetics, part of Exact Sciences
Significance: Likely benign
Review Status: no assertion criteria provided
Collection Method: clinical testing

This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.36
BayesDel_addAF
Benign
-0.25
T
BayesDel_noAF
Benign
-0.13
CADD
Uncertain
23
DANN
Uncertain
0.99
DEOGEN2
Benign
0.17
T;D;D
Eigen
Uncertain
0.47
Eigen_PC
Uncertain
0.49
FATHMM_MKL
Pathogenic
0.97
D
LIST_S2
Benign
0.83
T;.;T
M_CAP
Benign
0.077
D
MetaRNN
Benign
0.032
T;T;T
MetaSVM
Uncertain
0.57
D
MutationAssessor
Benign
1.3
.;L;L
PrimateAI
Uncertain
0.65
T
PROVEAN
Uncertain
-2.8
.;D;.
REVEL
Uncertain
0.45
Sift
Benign
0.24
.;T;.
Sift4G
Uncertain
0.059
T;T;.
Polyphen
1.0
.;D;D
Vest4
0.52
MutPred
0.43
Loss of disorder (P = 0.1633);Loss of disorder (P = 0.1633);Loss of disorder (P = 0.1633);
MVP
0.89
ClinPred
0.055
T
GERP RS
4.2
Varity_R
0.24
gMVP
0.34

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs149813580; hg19: chr17-18039039; API